Angiopoietin as A Novel Prognostic Marker in Kidney Disease
S. Karger AG, Basel..
Renal injury is among the leading causes of morbidity and mortality, however, there are no reliable indicators for determining the likelihood of developing CKD, CKD progression or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization and inflammation, and have been implicated as prognostic and predictive markers in AKI. Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the chronic kidney disease progression. This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings. There is a need for further large scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Blood purification - (2024) vom: 23. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yildiz, Abdullah B [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 23.01.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1159/000536439 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367527979 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367527979 | ||
| 003 | DE-627 | ||
| 005 | 20240124232216.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240124s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000536439 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1269.xml |
| 035 | |a (DE-627)NLM367527979 | ||
| 035 | |a (NLM)38262381 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yildiz, Abdullah B |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Angiopoietin as A Novel Prognostic Marker in Kidney Disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a S. Karger AG, Basel. | ||
| 520 | |a Renal injury is among the leading causes of morbidity and mortality, however, there are no reliable indicators for determining the likelihood of developing CKD, CKD progression or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization and inflammation, and have been implicated as prognostic and predictive markers in AKI. Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the chronic kidney disease progression. This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings. There is a need for further large scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications | ||
| 650 | 4 | |a Systematic Review | |
| 700 | 1 | |a Copur, Sidar |e verfasserin |4 aut | |
| 700 | 1 | |a Tanriover, Cem |e verfasserin |4 aut | |
| 700 | 1 | |a Yavuz, Furkan |e verfasserin |4 aut | |
| 700 | 1 | |a Vehbi, Sezan |e verfasserin |4 aut | |
| 700 | 1 | |a Gaipov, Abduzhappar |e verfasserin |4 aut | |
| 700 | 1 | |a Magagnoli, Lorenza |e verfasserin |4 aut | |
| 700 | 1 | |a Ciceri, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzolino, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Kanbay, Mehmet |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood purification |d 1993 |g (2024) vom: 23. Jan. |w (DE-627)NLM012656127 |x 1421-9735 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000536439 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 01 | ||